Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19277667 | 0.89 | SRD5A2 (0.31) | EPHX2 | |
| SCHEMBL23601329 | 0.84 | EPHX2 (0.37) | NPSR1ALDH1A1EPHX2TSHRGLA | |
| SCHEMBL420128 | 0.81 | GLA (0.46) | NPSR1ALDH1A1EPHX2TSHRGLA | |
| SCHEMBL3630405 | 0.80 | KMT2A (0.41) | NPSR1ALDH1A1HTTTSHRKMT2A | |
| SCHEMBL31623216 | 0.78 | — | — | |
| SCHEMBL30730055 | 0.74 | — | — | |
| SCHEMBL14697279 | 0.73 | HSD11B1 (0.45) | NPSR1ALDH1A1EPHX2TSHRKMT2A | |
| SCHEMBL3704482 | 0.72 | ALDH1A1 (0.42) | NPSR1ALDH1A1HTTTSHRGLA | |
| SCHEMBL29137733 | 0.71 | — | — | |
| SCHEMBL21503988 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516046-B2 | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20230227441-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227441-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227441-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4167994-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021257418-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227441-A1 | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | NPSR1 1017/4885ALDH1A1 1828/4885HTT 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.